Evidence map›Paper›PMID 37957722›Full record

ArticleJournal of nanobiotechnology2023

Intervening in hnRNPA2B1-mediated exosomal transfer of tumor-suppressive miR-184-3p for tumor microenvironment regulation and cancer therapy.

Xueqing Zhou, Yiling Hong, Yupeng Liu, Li Wang, Xuan Liu, Yi Li, Hong Yuan, Fuqiang Hu

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. HNRNPA2B1: a novel target in pulmonary arterial hypertension.Frontiers in cardiovascular medicine · 2025
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Exosome miRNA sorting controlled by RNA-binding protein-motif interactions.Extracellular vesicles and circulating nucleic acids · 2025
    Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xueqing ZhouCollege of pharmaceutical science, Zhejiang University, Hangzhou, 310058, China.
Yiling HongCollege of pharmaceutical science, Zhejiang University, Hangzhou, 310058, China.
Yupeng LiuCollege of pharmaceutical science, Zhejiang University, Hangzhou, 310058, China.
Li WangCollege of pharmaceutical science, Zhejiang University, Hangzhou, 310058, China.
Xuan LiuCollege of pharmaceutical science, Zhejiang University, Hangzhou, 310058, China.
Yi LiCollege of pharmaceutical science, Zhejiang University, Hangzhou, 310058, China.
Hong YuanCollege of pharmaceutical science, Zhejiang University, Hangzhou, 310058, China.
Fuqiang HuCollege of pharmaceutical science, Zhejiang University, Hangzhou, 310058, China. hufq@zju.edu.cn.
Zhejiang University · CN

Funding

China Postdoctoral Science Foundation 2018M630686National Natural Science Foundation of China 81973267Natural Science Foundation of Zhejiang Province LD19H300001
6 · The paper itself

Abstract

backgroundDespite being a common malignant tumor, the molecular mechanism underlying the initiation and progression of triple-negative breast cancers (TNBCs) remain unclear. Tumor-associated macrophages (TAMs) are often polarized into a pro-tumor phenotype and are associated with a poor prognosis of TNBCs. Exosomes, important mediators of cell-cell communication, can be actively secreted by donor cells to reprogram recipient cells. The functions and molecular mechanisms of tumor cell-derived exosomes in TNBCs progression and TAMs reprogramming urgently need to be further explored.

resultsWe demonstrated that tumor cell-derived exosomes enriched with miR-184-3p were taken up by macrophages to inhibit JNK signaling pathway by targeting EGR1, thereby inducing M2 polarization of macrophages and synergistically promoting tumor progression. Nanoparticles loaded with oncogene c-Myc inhibitor JQ1 could suppress the polarization process by reducing Rac1-related exosome uptake by macrophage. More importantly, it was found for the first time that tumor-suppressive miR-184-3p was actively sorted into exosomes by binding to RNA-binding protein heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1), thus facilitating tumor cell proliferation and metastasis by relieving the inhibitory effect of miR-184-3p on Mastermind-like 1 (MAML1). Overexpressing miR-184-3p in tumor cells and simultaneously knocking down hnRNPA2B1 to block its secretion through exosomes could effectively inhibit tumor growth and metastasis.

conclusionsOur study revealed that hnRNPA2B1-mediated exosomal transfer of tumor-suppressive miR-184-3p from breast cancer cells to macrophages was an important mediator of TNBCs progression, providing new insights into TNBCs pathogenesis and therapeutic strategies.

Indexed as

MicroRNAsNeoplasmsCell Line, TumorCell ProliferationTumor MicroenvironmentMicroRNAsExosomeshnRNPA2B1miR-184-3pNanoparticleTAMsTNBCs

Identifiers

PMID37957722
PMCPMC10644646
OpenAlexW4388670923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.